• Trevi Therapeutics announced Phase 2b CORAL trial results on oral nalbuphine ER were accepted for a future CHEST 2026 oral presentation.
• The data will be presented Oct. 20 at the CHEST 2026 Annual Meeting in Phoenix.
• Patient-reported outcomes indicated early, sustained improvement in chronic cough-related measures in idiopathic pulmonary fibrosis patients.
• The trial tested multiple oral nalbuphine ER doses versus placebo over six weeks in 165 patients, supporting the program’s clinical positioning.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Trevi Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610130730PRIMZONEFULLFEED9843148) on October 13, 2026, and is solely responsible for the information contained therein.